PUBLISHER: DelveInsight | PRODUCT CODE: 1226631
PUBLISHER: DelveInsight | PRODUCT CODE: 1226631
"PH94B Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about PH94B for Generalized Anxiety Disorder (GAD) in the seven major markets. A detailed picture of the PH94B for Generalized Anxiety Disorder in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the PH94B for Generalized Anxiety Disorder. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PH94B market forecast, analysis for Generalized Anxiety Disorder in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Generalized Anxiety Disorder.
VistaGen's PH94B is an innovative synthetic investigational neurosteroid developed from proprietary compounds called pherines. With its novel mechanism of action, PH94B is an odorless nasal spray administered at microgram-level doses to achieve rapid-onset of anti-anxiety, or anxiolytic, effects. The pharmacological activity of PH94B is fundamentally different from that of all FDA-approved anti-anxiety drugs. Importantly, PH94B does not require systemic uptake and distribution to produce its rapid-onset anti-anxiety effects. In all clinical trials to date, PH94B's safety profile has been excellent, with placebo-like side effects and no serious adverse events like those that are associated with the current FDA-approved treatment options.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PH94B Analytical Perspective by DelveInsight
This report provides a detailed market assessment of PH94B in Generalized Anxiety Disorder in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of PH94B.
The report provides the clinical trials information of PH94B in Generalized Anxiety Disorder covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions